J.D., Texas Tech University summa cum laude
Ph.D., Biomedical Sciences, Texas Tech University Health Sciences Center
B.S., Biology, minor in Music, Trinity University cum laude
District of Columbia
United States Patent & Trademark Office
Dr. Aldrich is an associate in the Biotechnology group. He assists in the preparation and prosecution of U.S. and foreign patent applications and in the preparation of freedom to operate and patentability opinions. He also has experience in inter partes review proceedings. Dr. Aldrich's primary areas of technical expertise include immunology, microbiology, vaccines, cancer biology, and molecular biology.
Dr. Aldrich earned his Ph.D. in Biomedical Sciences, with a concentration in Medical Microbiology, from Texas Tech University Health Sciences Center. There, his research focused on the elucidation of immune mechanisms underlying DNA vaccination against a tumor-specific antigen. His research demonstrated that CD4+ T lymphocytes and Th1 effector components are critical mediators of DNA vaccine-induced tumor immunity to virally-transformed tumor cells. While in graduate school, he received the Dean’s Scholars Award and the Mary Lou Clements-Mann Endowed Scholarship, and he was awarded the Dean’s Recognition Award at graduation.
As a law student, Dr. Aldrich served as editor-in-chief and editor-in-chief emeritus of the Journal of Biosecurity, Biosafety and Biodefense Law. He also served as a fellow at the Texas Tech University Center for Biodefense, Law and Public Policy and as a technology analyst at the Texas Tech University Office of Technology Commercialization. Following graduation, Dr. Aldrich was inducted into the Order of the Coif.
Aldrich JF. The Rise of the Mutants: Obtaining Regulatory Approval for the Release of Genetically Modified Mosquitoes. Colum. Sci. & Tech. L. Rev., Accepted for publication, 2015.
Aldrich JF. Legal Framework Surrounding the Development of Vaccines for Select Agents: Do the Legal Incentives Outweigh the Legal Burdens? 6 JBBBL 2015.
Bright JD, Aldrich JF, Byrne JA, Bright RK. Vaccination with the Prostate Cancer Over-Expressed Tumor Self-Protein TPD52 Elicits Protective Tumor Immunity and a Potentially Unique Subset of CD8+ T Cells. Austin J Clin Immunol, 1(2):id1007, 2014.
Aldrich JF, Shearer MH, Lowe DB, Winn RE, Jumper CA, Kennedy RC, Bright RK. The Role of Gamma Interferon in DNA Vaccine-Induced Tumor Immunity Targeting Simian Virus 40 Large Tumor Antigen. Cancer Immunol Immunother 62(2):371-82, 2013.
Aldrich JF, Winn RE, Shearer MH, Qin P, Karim MN, Kennedy RC. Progress on the Development of Universal Influenza Vaccines. Curr Top Virol 9:51-9, 2011.
Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Bright RK, Kennedy RC. CD4+ T Lymphocytes Are Critical Mediators of Tumor Immunity to Simian Virus 40 Large Tumor Antigen Induced by Vaccination with Plasmid DNA. J Virol 85(14):7216-24, 2011.
Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Kennedy RC. Vaccines and Immunotherapeutics for the Treatment of Malignant Disease. Clin Dev Immunol 2010:697158, 2010.
Lowe DB, Shearer MH, Aldrich JF, Winn RE, Jumper CA, Kennedy RC. Role of the Innate Immune Response and Tumor Immunity Associated with Simian Virus 40 Large Tumor Antigen. J Virol 84(19):10121-30, 2010.
Healy FG, Eaton KP, Limsirichai P, Aldrich JF, Plowman AK, King RR. Characterization of γ-Butyrolactone Autoregulatory Signaling Gene Homologs in the Angucyclinone Polyketide WS5995B Producer Streptomyces acidiscabies. J Bacteriol 191(15):4786-97, 2009.
Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler. If you are not already a client of Sterne Kessler, do not include any confidential information in this message.